SeaStar Medical Holding Corp (ICU)
| Market Cap | $6.27M-62.1% |
| Revenue (ttm) | $1.71M |
| Net Income | -$13.63M |
| EPS | -$2.71 |
| Shares Out | 5.32M |
| PE Ratio | n/a |
| Forward PE | -0.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 110,605 |
| Open | $1.06 |
| Previous Close | $1.04 |
| Day's Range | $1.03 - $1.19 |
| 52-Week Range | $0.76 - $5.38 |
| Beta | -1.04 |
| Analysts | Buy |
| Price Target | $10.00(+747.46%) |
| Earnings Date | n/a |
About ICU
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
SeaStar Medical Holding Corp Stock Analysis — InsiderScore
SeaStar Medical Holding Corp scored higher than 83% of companies evaluated by InsiderBuying, and ranked 15th out of 103 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at SeaStar Medical Holding Corp bought $8.7K of stock across 2 purchases in the last 90 days, the largest of them $6.6K.
The average purchase added about 64% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ICU stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ICU holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ICU's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ICU Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ICU patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ICU from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from ICU’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 2026 earnings with Qualimmune revenue growth and ongoing AKI study progress indicate solid commercial traction and development pipeline advancement.
Recent Insider Activity
Insider Score Trend Over Time
-0.8 since Nov 18Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
